With orphan drugs typically being high value, the potential risk of stock losses should be a top concern for biotechs looking ...

The European orphan drug market is growing and is already comparable in size and scope to the US market. The European Union ...

Neurotech has received positive feedback from the European Medicines Agency (EMA) on its orphan drug application for NTI164 to treat ... Read More The post Neurotech receives positive opinion for ...

The results show that HTAs for orphan drugs can vary widely across Europe, causing inconsistencies in evidence requirements and recommendations. The study reviewed all 80 European Medicines Agency ...

and the E.U.’s European Medicines Agency (EMA). “The granting of Orphan Drug Designation in these two jurisdictions confirms that we are on a relatively rapid and cost-effective path to market ...